- New, $110 million facility will more than double existing production capacity - Supports large-scale commercial manufacturing of viral and gene therapy products BURLINGTON, Mass., April 21, 2020 ...

In this free webinar, identify key bottlenecks in scaling viral vector manufacturing and gain practical insights to improve scalability. The featured speakers will discuss industry-wide challenges and ...

PLAINVILLE, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today expanded its cell and gene therapy capabilities with the opening of its new previously ...

Developed in collaboration with Korea's top clinical and hospital network, the integrated platform combines globally ...

A global contract developer says it is among the first to offer a standardized approach to manufacturing adeno-associated viruses (AAVs) and lentiviruses (LVVs) for advanced therapies. AGC Biologics ...

Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing demand. The purpose of the ...

Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...

The cell and gene therapy CDMO market is experiencing significant growth, driven by the increasing number of cell and gene therapy candidates advancing through clinical development and ...

DUBLIN--(BUSINESS WIRE)--The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the viral vectors ...

Matica Biotechnology, Inc. ("Matica Bio"), a leading viral vector contract development and manufacturing organization (CDMO) specializing in advanced therapies, is pleased to announce its engagement ...

The SK pharmteco group is now offering a standardized viral vector and plasmid manufacturing process to a global audience. The global approach can help customers move to batches for clinical trials in ...